Replidyne (RDYN)

[apostrophe]

Faropenem Phase III Clinical Trial Stopped to Consider Exclusion of Ketek Comparator

http://news.moneycentral.msn.com/ticker/article.aspx?Symbol=US:RDYN&Feed=PR&Date=20061226&am....

My impression is that this one may be on to something in regard to an improved treatment for staph. My impression is that the Phase III was interrupted due to the comparison/competitor (approved) drug causing problems. "..Committee recommended to the FDA that the risks of Ketek outweigh the benefits of using the drug for the treatment of patients with AECB in a 17 to 2 vote." (Competitor "approved" drug = KETEK)

Which implies that their new drug faropenem medoxomil is better.
And approval should be a shoo-in considering the inferior drug got previously approved...

I'm certainly not an expert on biotechs but it seems that their product market is similar to Staph drug /hospital market targetted by VPHM. I beleive that VPHM has done well with their product in the past, so, it seems possible that RDYN may be in a good position.

PPS is likely low and volume is sparse because RDYN seems to be completely unknown in the investment community (no other boards found so far) and it may be that people read the headline about Phase III stopped without noticing that it was stopped because of the competitor product, not, RDYN's...